Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

PHASE3TerminatedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

December 31, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Ruxolitinib

5 mg tablets to be administered by mouth twice daily (BID)

DRUG

Placebo

5 mg tablets to be administered by mouth twice daily (BID)

DRUG

Capecitabine

150 and 500 mg tablets to be administered by mouth twice daily (BID)

Trial Locations (230)

Unknown

Avondale

Chandler

Gilbert

Glendale

Mesa

Phoenix

Scottsdale

Surprise

Tucson

Hot Springs

Jonesboro

Anaheim

Bakersfield

Berkeley

Beverly Hills

Chula Vista

Covina

Downey

El Cajon

Fullerton

Gilroy

Glendale

La Mesa

Long Beach

Los Angeles

Lynwood

Modesto

Montebello

Northridge

Oceanside

Orange

Redondo Beach

San Diego

San Francisco

San Luis Obispo

Santa Ana

Santa Maria

Santa Monica

Torrance

Whittier

Aurora

Boulder

Colorado Springs

Denver

Grand Junction

Longmont

Thornton

New Britain

New Haven

Southington

Trumbull

Newark

Boca Raton

Hollywood

Miami

Pembroke Pines

Atlanta

Austell

Carrollton

Cartersville

Douglasville

Marietta

Newnan

Rome

Thomasville

Arlington Heights

Chicago

Hinsdale

Niles

Urbana

Goshen

Indianapolis

Topeka

Ashland

Louisville

Metairie

New Orleans

Scarborough

Annapolis

Baltimore

Bethesda

Rockville

Worcester

Ann Arbor

Detroit

Kalamazoo

Lansing

Woodbury

Bolivar

Kansas City

St Louis

Kalispell

Hastings

Omaha

Papillion

Las Vegas

Lebanon

East Orange

Farmington

Binghamton

Fresh Meadows

Hudson

Johnson City

New York

Nyack

Rochester

The Bronx

Durham

Wake Forest

Winston-Salem

Canton

Columbus

Middletown

Oregon

Toledo

Eugene

Portland

Springfield

Tualatin

Philadelphia

Charleston

Seneca

Spartanburg

Chattanooga

Knoxville

Memphis

Nashville

Arlington

Austin

Beaumont

Bedford

Cedar Park

Dallas

Denton

El Paso

Fort Worth

Houston

Plano

Round Rock

San Antonio

Temple

Tyler

Waco

Ogden

Salt Lake City

Blacksburg

Richmond

Roanoke

Salem

Wytheville

Seattle

Vancouver

Madison

Australian Capital Territory

New South Wales

South Australia

Victoria

Aalst

Bruges

Brussels

Edegem

Ghent

Gilly

Kortrijk

Leuven

Calgary

Oshawa

Sault Ste. Marie

Toronto

Greenfield Park

Laval

Montreal

Aschaffenburg

Berlin

Bochum

Cologne

Essen

Frankford

Velbert

Aviano

Bari

Bergamo

Brescia

Cremona

Florence

Genova

Lido di Camaiore

Milan

Napoli

Pisa

Rimini

Roma

Auckland

Christchurch

Hamilton

Hwasun-gun

Seongnam-si

Seoul

Badajoz

Barcelona

Madrid

Málaga

Seville

Taichung

Tainan City

Taipei

Patumwan

Ratchathewi

Seetatarom

Aberdeen

Bangor

Birmingham

Boston

Bristol

Cardiff

Glasgow

Guildford

Harlow

Huddersfield

Lancaster

Leeds

London

Manchester

Metropolitan Borough of Wirral

Newcastle upon Tyne

Nottingham

Plymouth

Southampton

Sutton

Welwyn Garden City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT02117479 - Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Biotech Hunter | Biotech Hunter